Serum matrix metalloproteinase-1 level represents disease activity as opposed to fibrosis in patients with histologically proven nonalcoholic steatohepatitis.
- Author:
Wataru ANDO
1
;
Hiroaki YOKOMORI
;
Nobuhiro TSUTSUI
;
Eigoro YAMANOUCHI
;
Yutaka SUZUKI
;
Masaya ODA
;
Yutaka INAGAKI
;
Katsuya OTORI
;
Isao OKAZAKI
Author Information
- Publication Type:Original Article
- Keywords: Nonalcoholic steatohepatitis; Matrix metalloprotease 1; Cytokines; Liver cirrhosis
- MeSH: Biomarkers; Carcinoma, Hepatocellular; Chemokine CCL2; Cytokines; Developing Countries; Early Diagnosis; Fibrosis*; Follow-Up Studies; Hepatic Stellate Cells; Humans; Kupffer Cells; Liver Cirrhosis; Matrix Metalloproteinase 1*; Matrix Metalloproteinases; Metalloproteases; Monocytes; Non-alcoholic Fatty Liver Disease*
- From:Clinical and Molecular Hepatology 2018;24(1):61-76
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND/AIMS: Nonalcoholic steatohepatitis (NASH) is prevalent in both economically developed and developing countries. Twenty percent of NASH progresses to cirrhosis with/without hepatocellular carcinoma, and there is an urgent need to find biomarkers for early diagnosis and monitoring progression of the disease. Using immunohistochemical and immunoelectron microscopic examination we previously reported that expression of matrix metalloproteinase-1 (MMP-1) increased in monocytes, Kupffer cells and hepatic stellate cells in early stage NASH. The present study investigated whether serum MMP-1 levels reflect disease activity and pharmaceutical effects in NASH patients. METHODS: We measured the serum levels of MMPs, tissue inhibitors of metalloproteinases (TIMPs), and several cytokines/chemokines in patients with histologically proven early and advanced stages of NASH and compared them with those in healthy controls. RESULTS: Serum MMP-1 levels in stage 1 fibrosis, but not in the more advanced fibrosis stages, were significantly higher than in healthy controls (P=0.019). There was no correlation between serum MMP-1 level and fibrosis stage. Serum MMP- 1 levels in NASH patients represented disease activity estimated by serum aminotransferase values during the follow-up period. In contrast, MMP-2, MMP-9 and TIMPs did not change with disease activity. Consistent with the finding that MMP-1 is expressed predominantly in monocytes and Kupffer cells, serum levels of monocyte chemotactic protein-1 and granulocyte-colony stimulating factor were significantly increased in NASH with stage 1 fibrosis. CONCLUSIONS: These results suggest that serum MMP-1 levels represent disease activity and may serve as a potential biomarker for monitoring the progression of NASH.
